Comparison of in vitro Susceptibilities of Talaromyces marneffei in Mold and Yeast Forms in Malaysia

References

• Mohd Nizam T. Epidemiological and clinical features of talaromycosis (Penicilliosis) Marneffei among human immunodeficiency virus-infected patients in Malaysia. MedHealth. 2018;13(2):103–113. doi:10.17576/MH.2018.1302.10
   Google Scholar
• Xu X, Ran X, Pradhan S, Lei S, Ran Y. Dermoscopic manifestations of Talaromyces (Penicillium) marneffei infection in an AIDS patient. Indian J Dermatol Venereol Leprol. 2019;85(3):348. doi:10.4103/IJDVL.IJDVL_118_17
   PubMed Web of Science ®Google Scholar
• Velayuthan RD, Samudi C, Singh HKL, Ng KP, Shankar EM, Denning DW. Estimation of the burden of serious human fungal infections in Malaysia. J Fungi. 2018;4(1):38. doi:10.3390/JOF4010038
   Web of Science ®Google Scholar
• Chen J, Zhang R, Shen Y, et al. Clinical characteristics and prognosis of penicilliosis among human immunodeficiency virus-infected patients in eastern China. Am J Trop Med Hyg. 2017;96(6):1350–1354. doi:10.4269/AJTMH.16-0521
   PubMed Web of Science ®Google Scholar
• HKMJ. Clinical presentations and outcomes of Penicillium marneffei infections: a series from 1994 to 2004. Available from: https://www.hkmj.org/abstracts/v14n2/103.htm. Accessed November 21, 2022.
   Google Scholar
• Lau SKP, Lo GCS, Lam CSK, et al. In Vitro Activity of Posaconazole against Talaromyces marneffei by broth microdilution and Etest methods and comparison to itraconazole, voriconazole, and anidulafungin. Antimicrob Agents Chemother. 2017;61(3). doi:10.1128/AAC.01480-16
   Web of Science ®Google Scholar
• Vanittanakom N, Cooper CR, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19(1):95–110. doi:10.1128/CMR.19.1.95-110.2006
   PubMed Web of Science ®Google Scholar
• Baradkar V, Kumar S, Kulkarni SD. Penicillium marneffei: the pathogen at our doorstep. Indian J Dermatol Venereol Leprol. 2009;75(6):619–620. doi:10.1258/jrsm.97.8.394
   PubMed Web of Science ®Google Scholar
• Liu Y, Huang X, Yi X, He Y, Mylonakis E, Xi L. Detection of Talaromyces marneffei from fresh tissue of an inhalational murine pulmonary model using nested PCR. PLoS One. 2016;11(2):e0149634. doi:10.1371/JOURNAL.PONE.0149634
   PubMed Web of Science ®Google Scholar
• Klein BS, Tebbets B. Dimorphism and virulence in fungi. Curr Opin Microbiol. 2007;10(4):314–319. doi:10.1016/J.MIB.2007.04.002
   PubMed Web of Science ®Google Scholar
• Yuen WC, Chan YF, Loke SL, Seto WH, Poon GP, Wong KK. Chronic lymphadenopathy caused by Penicillium marneffei: a condition mimicking tuberculous lymphadenopathy. Br J Surg. 1986;73(12):1007–1008. doi:10.1002/BJS.1800731224
   PubMed Web of Science ®Google Scholar
• Pautler KB, Padhye AA, Ajello L. Imported penicilliosis marneffei in the United States: report of a second human infection. Sabouraudia. 1984;22(5):433–438. doi:10.1080/00362178485380691
   PubMedGoogle Scholar
• Deng Z, Connor DH. Progressive disseminated penicilliosis caused by Penicillium marneffei. Report of eight cases and differentiation of the causative organism from Histoplasma capsulatum. Am J Clin Pathol. 1985;84(3):323–327. doi:10.1093/AJCP/84.3.323
   PubMed Web of Science ®Google Scholar
• Arifin WN. Introduction to sample size calculation. Educ Med J. 2013;5(2). doi:10.5959/eimj.v5i2.130
   Google Scholar
• Kiss L. Limits of nuclear ribosomal DNA internal transcribed spacer (ITS) sequences as species barcodes for Fungi. Proc Natl Acad Sci U S A. 2012;109(27):E1811. doi:10.1073/PNAS.1207143109
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• Sar B, Boy S, Keo C, et al. In vitro antifungal-drug susceptibilities of mycelial and yeast forms of Penicillium marneffei Isolates in Cambodia. J Clin Microbiol. 2006;44(11):4208. doi:10.1128/JCM.00902-06
   PubMed Web of Science ®Google Scholar
• Tan XT, Shuhairi LM, Jane S, Shukor SM, Amran F. Comparison of yeast and fungus form in vitro susceptibilities of Sporothrix schenckii in Malaysia: in vitro susceptibility of Sporothrix schencki. Southeast Asian J Trop Med Public Health. 2022;53(5):469–478.
   Web of Science ®Google Scholar
• Sekhon AS, Garg AK, Padhye AA, Hamir Z. In vitro susceptibility of mycelial and yeast forms of Penicillium marneffei to amphotericin B, fluconazole, 5-fluorocytosine and itraconazole. Eur J Epidemiol. 1993;9(5):553–558. doi:10.1007/BF00209535
   PubMed Web of Science ®Google Scholar
• Melanization of pathogenic fungi, particularly Aspergillus fumigatus and Penicillium marneffei - Aspergillus and Aspergillosis. Available from: https://www.aspergillus.org.uk/conference_abstracts/melanization-of-pathogenic-fungi-particularly-aspergillusfumigatus-and-penicillium-marneffei/. Accessed January 3, 2023.
   Google Scholar
• Nosanchuk JD, Casadevall A. The contribution of melanin to microbial pathogenesis. Cell Microbiol. 2003;5(4):203–223. doi:10.1046/J.1462-5814.2003.00268.X
   PubMed Web of Science ®Google Scholar
• Youngchim S, Youngchim S. Talaromyces marneffei infection: virulence factors and rapid diagnostics. Infect Diss Ann. 2022. doi:10.5772/INTECHOPEN.108592
   Google Scholar
• Kaewmalakul J, Nosanchuk JD, Vanittanakom N, Youngchim S. Melanization and morphological effects on antifungal susceptibility of Penicillium marneffei. Antonie Van Leeuwenhoek. 2014;106(5):1011. doi:10.1007/S10482-014-0270-9
   PubMed Web of Science ®Google Scholar
• Singh RB, Devi KR. A comparative study on antifungal susceptibility of Penicillium marneffei (Talaromyces marneffei) and nonmarneffei Penicillium species. J Med Soc. 2018;32(1):22. doi:10.4103/JMS.JMS_38_17
   Google Scholar
• Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother. 1993;37(11):2407–2411. doi:10.1128/AAC.37.11.2407
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Cai S, Liang H, Cao C. Administration of voriconazole in disseminated Talaromyces (Penicillium) marneffei infection: a retrospective study. Mycopathologia. 2017;182(5–6):569–575. doi:10.1007/S11046-016-0107-3
   PubMed Web of Science ®Google Scholar
• Liu D, Liang L, Chen J. In vitro antifungal drug susceptibilities of Penicillium marneffei from China. J Infect Chemother. 2013;19(4):776–778. doi:10.1007/S10156-012-0511-7
   PubMed Web of Science ®Google Scholar
• Petranyi G, Ryder NS, Stütz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science. 1984;224(4654):1239–1241. doi:10.1126/SCIENCE.6547247
   PubMed Web of Science ®Google Scholar
• Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother. 1987;31(9):1365–1368. doi:10.1128/AAC.31.9.1365
   PubMed Web of Science ®Google Scholar
• Ryder NS. Effect of allylamine antimycotic agents on fungal sterol biosynthesis measured by sterol side-chain methylation. J Gen Microbiol. 1985;131(7):1595–1602. doi:10.1099/00221287-131-7-1595
   PubMedGoogle Scholar
• Mcginnis MR, Nordoff NG, Ryder NS, Nunn GB. In Vitro Comparison of Terbinafine and Itraconazole against Penicillium marneffei. Antimicrob Agents Chemother. 2000;44(5):1407–1408. doi:10.1128/AAC.44.5.1407-1408.2000
   PubMed Web of Science ®Google Scholar
• Fang L, Liu M, Huang C, et al. MALDI-TOF MS-based clustering and antifungal susceptibility tests of talaromyces marneffei isolates from Fujian and Guangxi (China). Infect Drug Resist. 2022;15:3449–3457. doi:10.2147/IDR.S364439
   PubMed Web of Science ®Google Scholar
• Lei HL, Li LH, Chen WS, et al. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China. Eur J Clin Microbiol Infect Dis. 2018;37(6):1099–1102. doi:10.1007/S10096-018-3222-X
   PubMed Web of Science ®Google Scholar
• Ashbee HR, Gilleece MH. Pharmacogenomics of antifungal agents. In: Handbook of Pharmacogenomics and Stratified Medicine. Academic Press; 2014:879–900. doi:10.1016/B978-0-12-386882-4.00038-4
   Google Scholar
• Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother. 2004;48(2):568–574. doi:10.1128/AAC.48.2.568-574.2004
   PubMed Web of Science ®Google Scholar
• Szyma Nski M, Chmielewska S, Czy_ Zewska U, Malinowska M, Tylicki A. Echinocandins-structure, mechanism of action and use in antifungal therapy. J Enzyme Inhib Med Chem. 2022;37(1):876–894. doi:10.1080/14756366.2022.2050224
   PubMed Web of Science ®Google Scholar
• Ministry of Health Malaysia. National antimicrobial guidelines. Officially Launched on 26th; 2019. Available from: www.pharmacy.gov.my. Accessed March 13, 2023.
   Google Scholar